Indications
Small cell lung cancer
Doxorubicin is an anthracycline topoisomerase II inhibitor indicated for:
Ovarian cancer: After failure of platinum-based chemotherapy.
AIDS-related Kaposi’s Sarcoma: After failure of prior systemic chemotherapy or intolerance to such therapy.
... Read more
Doxorubicin is an anthracycline topoisomerase II inhibitor indicated for:
Ovarian cancer: After failure of platinum-based chemotherapy.
AIDS-related Kaposi’s Sarcoma: After failure of prior systemic chemotherapy or intolerance to such therapy.
Multiple Myeloma: In combination with bortezomib in patients who have not previously received bortezomib and have received at least one prior therapy.
Dosage And Administration
Administer Doxorubicin at an initial rate of 1 mg/min to minimize the risk of infusion reactions. If no infusion related reactions occur, increase rate of infusion to complete administration over 1 hour. Do not administer as bolus injection or undiluted solution.
Ovarian cancer: 50 mg/m2 IV every 4 weeks
AIDS-related Kaposi’s Sarcoma: 20 mg/m2 IV every 3 weeks
Multiple Myeloma: 30 mg/m2 IV on day 4 following bortezomib
Side Effects
Leucopenia, thrombocytopenia, nausea, vomiting, diarrhoea. Rarely facial flushing, rash, alopecia. Blurred vision, headache, seizures, paraesthesia, confusion, malaise, lethargy, skin pigmentation.
Precautions And Warnings
Elderly, children, hepatic impairment. Monitor blood counts and ECG.
Pregnancy And Lactation
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective).